Search - tctmd.com

Displaying 141 - 160 of 374

Sort: Relevancy | Date

In Long-term, Real-world Data CABG Bests PCI for Diabetic Patients With MVD

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

August 12, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

August 03, 2020

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

News Daily News

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Michael O'Riordan

June 22, 2020

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

June 11, 2020

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

News Daily News

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

May 28, 2020

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

January 14, 2020

Diabetes Does Not Appear to Hinder FFR Insights for CAD

News Daily News

Diabetes Does Not Appear to Hinder FFR Insights for CAD

January 09, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

October 02, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.